Telisotuzumab Adizutecan clinical trials
6 indexed studies · 5 currently recruiting
- RecruitingPHASE2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new combination of medicines for advanced bowel cancer. It aims to see how safe and effective a new drug, telisotuzumab adizutecan, is when given with standard treatments. The study will look at side effects and whether the cancer activity changes.
For: Metastatic Colorectal CancerUnited States · Australia · Austria - RecruitingPHASE2, PHASE3
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
This study looks at a new drug, telisotuzumab adizutecan, for a type of lung cancer called non-small cell lung cancer. It compares the new drug to standard treatments to see how safe it is and how well it works in adults with advanced lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Austria - RecruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
For: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal AdenocarcinomaUnited States · Belgium · Canada - RecruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
For: Metastatic Pancreatic Ductal Adenocarcinoma · PDACUnited States · Australia · Israel - RecruitingPHASE1, PHASE2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
This study looks at new drug combinations for advanced lung cancer. It combines telisotuzumab adizutecan with immune-boosting drugs like budigalimab or pembrolizumab. The goal is to find safe and effective doses to help people with non-small cell lung cancer who haven't had prior treatment for advanced disease.
For: Non Small Cell Lung CarcinomaUnited States · Belgium · China - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification
This study is looking at a new drug, Telisotuzumab Adizutecan, for people with advanced solid cancers that have a specific genetic change called 'MET amplification'. Researchers want to see how safe and effective this drug is at shrinking these cancers.
For: Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification geneSpain · France · Denmark